Details

Autor(en) / Beteiligte

• Paiva, Bruno
• Vidriales, Maria-Belén
• Mateo, Gema
• Pérez, Jose J.
• Montalbán, Maria Angeles
• Sureda, Anna
• Montejano, Laura
• Gutiérrez, Norma C.
• García de Coca, Alfonso
• de las Heras, Natalia
• Mateos, Maria Victoria
• López-Berges, Maria Consuelo
• García-Boyero, Raimundo
• Galende, Josefina
• Hernández, Jose
• Palomera, Luis
• Carrera, Dolores
• Martínez, Rafael
• de la Rubia, Javier
• Martín, Alejandro
• González, Yolanda
• Bladé, Joan
• Lahuerta, Juan José
• Orfao, Alberto
• San-Miguel, Jesús F.
• on behalf of the GEM (Grupo Español de MM)/PETHEMA (Programa para el Estudio de la Terapéutica en Hemopatías Malignas) Cooperative Study Groups

Titel

The persistence of immunophenotypically normal residual bone marrow plasma cells at diagnosis identifies a good prognostic subgroup of symptomatic multiple myeloma patients

Ist Teil von

• Blood, 2009-11, Vol.114 (20), p.4369-4372

Ort / Verlag

Washington, DC: Elsevier Inc

Erscheinungsjahr

2009

Quelle

MEDLINE

Beschreibungen/Notizen

• Multiparameter flow cytometry immunophenotyping allows discrimination between normal (N-) and myelomatous (MM-) plasma cells (PCs) within the bone marrow plasma cell compartment (BMPCs). Here we report on the prognostic relevance of detecting more than 5% residual normal plasma cells from all bone marrow plasma cells (N-PCs/BMPCs) by multiparameter flow cytometry in a series of 594 newly diagnosed symptomatic MM patients, uniformly treated according to the Grupo Español de MM 2000 (GEM2000) protocol. Our results show that symptomatic MM patients with more than 5% N-PCs/BMPCs (n = 80 of 594; 14%) have a favorable baseline clinical prospect, together with a significantly lower frequency of high-risk cytogenetic abnormalities and higher response rates. Moreover, this group of patients had a significantly longer progression-free survival (median, 54 vs 42 months, P = .001) and overall survival (median, not reached vs 89 months, P = .04) than patients with less than or equal to 5% N-PCs/BMPCs. Our findings support the clinical value of detecting residual normal PCs in MM patients at diagnosis because this reveals a good prognostic category that could benefit from specific therapeutic approaches. This trial was registered at www.clinicaltrials.gov as NCT00560053.